Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country

International Journal of Molecular Epidemiology and Genetics

Volumn 3, Issue 1, 2012, Pages 56-65

  Diallo, Karidia ^a   Murillo, Wendy E ^b,c   de Rivera, Ivette Lorenzana ^b   Albert, Jan ^c   Zhou, Zhiyong ^a   Nkengasong, John ^a   Zhang, Guoqing ^a   Sabatier, Jennifer F ^a   Yang, Chunfu ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Concordance; Discordance; HIV 1 drug resistance; PBMCs; Resistance profile; Resource limited setting; RNA

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; DNA; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADULT; ALGORITHM; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONDURAS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SEQUENCE ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863358812     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. UNAIDS. UNAIDS World AIDS Day Report 2011. http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf. Accessed on January 10, 2012.
2. WHO. Global Report: UNAIDS Report on the Global AIDS Epidemic, 2010. http://www.unaids.org/globalreport/Global_report.htm. Accessed on January 10, 2011.
3. Wheeler DA, Arathoon EG, Pitts M, Cedillos RA, Bu TE, Porras GD, Herrera G and Sosa NR. Availability of HIV care in Central America. JAMA 2001; 286: 853-860.
4. Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, Karlsson AC and Albert J. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 2010; 11: 95-103.
5. Lloyd B, O'Connell RJ, Michael NL, Aviles R, Palou E, Hernandez R, Cooley J and Jagodzinski LL. Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Research & Human Retroviruses 2008; 24: 529-535.
6. Assefa DE, Abegaz W, Gedif T. et al., Evaluation of dried blood spots (DBS) for human immunodeficiecy virus (HIV-1) drug resistance testing. APHL HIV Diagnostics Conference, 2010; Orlando.
7. WHO manual for HIV drug resistance testing using dried blood spot specimens. World Health Organization, March 2010. Available from: http://www.who.int/hiv/topics/drugresistance/dbs_protocol.pdf [Last accessed: 19 October, 2011]. 2010.
8. th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2011, Rome, Italy.
9. Usuku S, Noguchi Y, Sakamoto M, Adachi T, Sagara H, Sudo K, Nishizawa M, Kondo M, Tochikubo O and Imai M. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient. Jpn J Infect Dis 2006; 59: 122-125.
10. Poveda E, Briz V, Paraskevis D, Barreiro P, Hat-zakis A and Soriano V. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses 2007; 23: 1078-1082.
11. Kaye S, Comber E, Tenant-Flowers M and Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses 1995; 11: 1221-1225.
12. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A and Johnson M. Substantial correla- tion between HIV type 1 drug-associated resis- tance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses 2000; 16: 1025-1030.
13. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE and Saksena NK. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005; 33: 206-216.
14. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD and Paranjape RS. Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India. AIDS Research & Human Retroviruses 2007; 23: 489-497.
15. Tagliaferro L, Menegazzi P, Cataldini S, De Simone M, Chiriaco P and Varnier OE. Drug resistance testing in PBMCs of HIV infected patients. New Microbiol 2001; 24: 325-332.
16. Smith DM, Wong JK, Shao H, Hightower GK, Mai SH, Moreno JM, Ignacio CC, Frost SD, Richman DD and Little SJ. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196: 356360.
17. Sarmati L, Nicastri E, Uccella I, D'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Concia E, Vullo V, Vella S and Andreoni M. Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 2003; 41: 1760-1762.
18. Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L and Gerna G. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001; 65: 207-217.
19. McDermott JL, Giri AA, Martini I, Bono M, Giacomini M, Campelli A, Tagliaferro L, Cara A and Varnier OE. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol 1999; 37: 2361-2365.
20. Karlsson AC, Chapman JM, Heiken BD, Hoh R, Kallas EG, Martin JN, Hecht FM, Deeks SG and Nixon DF. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol 2007; 81: 11543-11548.
21. Bon I, Gibellini D, Borderi M, Alessandrini F, Vitone F, Schiavone P and Re MC. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007; 38: 313-320.
22. Bon I, Alessandrini F, Borderi M, Gorini R and Re MC. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol 2007; 30: 313-317.
23. Soto-Ramirez LE, Rodriguez-Diaz R, Duran AS, Losso MH, Salomon H, Gomez-Carrillo M, Pampuro S, Harris DR, Duarte G, De Souza RS, Read JS and Group NPS. Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Research & Human Retroviruses 2008; 24: 797-804.
24. Lindstrom A, Albert J. A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods 2003; 107: 45-51.
25. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim S, Wadonda-Kabondo N, Aberle-Grasse J, Kibuka T, Ndumbe PM, Vedapuri S, Zhou Z, Chilima B and Nkengasong JN. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48: 3158-3164.
26. Zhou Z, Wagar N, Devos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J and Yang C. Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings. PLoS One 2011; 6: e28184.
27. Tamura K, Dudley J, Nei M and Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol.Biol. Evol. 2007; 24: 1596-1599.
28. Monno L, Punzi G, Scarabaggio T, Saracino A, Brindicci G, Fiore JR, Iambrenghi OC, Di Stefano M, Pastore G and Angarano G. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. J Med Virol 2003; 70: 1-9.
29. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV and Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72: 2422-2428.
30. Prakash R. DNA structure is more stable than RNA structure. http://www.brighthub.com/science/genetics/articles/16332.aspx. Accessed on October 19, 2009. Int J Mol Epidemiol Genet 2012;3(1):56-6.